<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34477330</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study.</ArticleTitle><Pagination><StartPage>1991</StartPage><EndPage>1999</EndPage><MedlinePgn>1991-1999</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51446</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Neuroinflammation is an important pathogenic mechanism in amyotrophic lateral sclerosis (ALS), with regulatory T cells (Tregs) mediating a slower rate of disease progression. Dimethyl fumarate enhances Treg levels and suppresses pro-inflammatory T cells. The present study assessed the safety and efficacy of dimethyl fumarate in ALS.</AbstractText><AbstractText Label="METHODS">Phase-2, double-blind, placebo-controlled randomised clinical trial recruited participants from May 1, 2018 to September 25, 2019, across six Australian sites. Participants were randomised (2:1 ratio) to dimethyl fumarate (480&#xa0;mg/day) or matching placebo, completing visits at screening, baseline, weeks 12, 24 and 36. The primary efficacy endpoint was a change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) at week 36. Secondary outcome measures included survival, neurophysiological index (NI), respiratory function, urinary neurotrophin-receptor p75 and quality of life.</AbstractText><AbstractText Label="RESULTS">A total of 107 participants were randomised to dimethyl fumarate (n&#xa0;=&#xa0;72) or placebo (n&#xa0;=&#xa0;35). ALSFRS-R score was not significantly different at week 36 (-1.12 [-3.75 to 1.52, p&#xa0;=&#xa0;0.41]). Dimethyl fumarate was associated with a reduced NI decline week 36 (differences in the least-squares mean: (0.84 [-0.51 to 2.22, p&#xa0;=&#xa0;0.22]). There were no significant differences in other secondary outcome measures. Safety profiles were comparable between groups.</AbstractText><AbstractText Label="INTERPRETATION">Dimethyl fumarate, in combination with riluzole, was safe and well-tolerated in ALS. There was no significant improvement in the primary endpoint. The trial provides class I evidence for safety and lack of efficacy of dimethyl fumarate in ALS.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8323-873X</Identifier><AffiliationInfo><Affiliation>Brain and Nerve Research Centre, Concord Clinical School, Concord Hospital, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Royal Brisbane &amp; Women's Hospital, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathers</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Calvary Health Care Bethlehem, Caulfield South, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Needham</LastName><ForeName>Merrilee</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fiona Stanley Hospital, Murdoch University, Murdoch, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Nedlands, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Notre Dame, Fremantle, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Flinders Medical Centre, Bedford Park, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-9054-026X</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>TEALS study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>FO2303MNI2</RegistryNumber><NameOfSubstance UI="D000069462">Dimethyl Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069462" MajorTopicYN="N">Dimethyl Fumarate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Prof SV&#x2010; reports received honoraria from Merck Serono Australia, advisory board Biogen Idec Australia. Unrelated to this manuscript. Dr RH reports no disclosures. Dr SM reports no disclosures. Dr MN reports no disclosures. Dr DS reports no disclosures. Prof MCK&#x2010; reports no disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>3</Day><Hour>8</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34477330</ArticleId><ArticleId IdType="pmc">PMC8528453</ArticleId><ArticleId IdType="doi">10.1002/acn3.51446</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et&#xa0;al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17:104&#x2010;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et&#xa0;al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2010;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Westeneng HJ, Al&#x2010;Chalabi A, Van Den Berg LH, Talman P, Kiernan MC. Amyotrophic lateral sclerosis as a multi&#x2010;step process: an Australia population study. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:532&#x2010;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">31284763</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Higashihara M, Sobue G, et&#xa0;al. ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology. 2020;94:e1657&#x2010;e1663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251515</ArticleId><ArticleId IdType="pubmed">32071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Braak H, Del Tredici K, Lemon R, Ludolph AC, Kiernan MC. Cortical influences drive amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:917&#x2010;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">28710326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose&#x2010;ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425&#x2010;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group EM&#x2010;ASG . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16:505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, et&#xa0;al. Masitinib as an add&#x2010;on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:5&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et&#xa0;al. Trial of sodium phenylbutyrate&#x2010;taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919&#x2010;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31:635&#x2010;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Liao B, et&#xa0;al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun. 2011;25:1025&#x2010;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, et&#xa0;al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293&#x2010;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci USA. 2008;105:15558&#x2010;15563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, et&#xa0;al. Association of regulatory T&#x2010;cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75:681&#x2010;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, et&#xa0;al. ALS patients&#x2019; regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2:e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajabinejad M, Ranjbar S, Afshar Hezarkhani L, Salari F, Gorgin Karaji A, Rezaiemanesh A. Regulatory T cells for amyotrophic lateral sclerosis/motor neuron disease: a clinical and preclinical systematic review. J Cell Physiol. 2020;235:5030&#x2010;5040.</Citation><ArticleIdList><ArticleId IdType="pubmed">31788795</ArticleId></ArticleIdList></Reference><Reference><Citation>Camu W, Mickunas M, Veyrune J&#x2010;L, et&#xa0;al. Repeated 5&#x2010;day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. EBioMedicine. 2020;59:102844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7502670</ArticleId><ArticleId IdType="pubmed">32651161</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, et&#xa0;al. Expanded autologous regulatory T&#x2010;lymphocyte infusions in ALS: a phase I, first&#x2010;in&#x2010;human study. Neurol Neuroimmunol Neuroinflamm. 2018;5:e465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold R, Kappos L, Arnold DL, et&#xa0;al. Placebo&#x2010;controlled phase 3 study of oral BG&#x2010;12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098&#x2010;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">22992073</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox RJ, Miller DH, Phillips JT, et&#xa0;al. Placebo&#x2010;controlled phase 3 study of oral BG&#x2010;12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087&#x2010;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">22992072</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Ryder J, Mekhael L, et&#xa0;al. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant). Medicine. 2020;99:e18904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7015658</ArticleId><ArticleId IdType="pubmed">32028398</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et&#xa0;al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497&#x2010;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et&#xa0;al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, et&#xa0;al. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137&#x2010;1143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Scotto M, Lopes A, Swash M. Quantitating progression in ALS. Neurology. 2005;64:1783&#x2010;1785.</Citation><ArticleIdList><ArticleId IdType="pubmed">15911812</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W, Dharmadasa T, Vucic S, Kiernan MC. Functional biomarkers for amyotrophic lateral sclerosis. Front Neurol. 2018;9:1141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6328463</ArticleId><ArticleId IdType="pubmed">30662429</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav SK, Soin D, Ito K, Dhib&#x2010;Jalbut S. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis. J Mol Med. 2019;97:463&#x2010;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">30820593</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen AB, Bostock H, Tankisi H. Following disease progression in motor neuron disorders with 3 motor unit number estimation methods. Muscle Nerve. 2019;59:82&#x2010;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">30025164</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>